& Macular Degeneration
Age-related macular degeneration (AMD) is a progressive eye disease and a leading cause of blindness, affecting more than 9 million people in the U.S. alone. Retinitis pigmentosa (RP) and other macular degenerations affect hundreds of thousands more. These diseases impact an area of the retina called the macula where detailed central vision occurs. Numerous clinical studies have shown that dark adaptation—the recovery of vision when going from daylight to darkness—is dramatically impaired from the earliest stages of AMD, RP and other macular degenerations, with increasing impairment as the diseases progress.
The AdaptDx® is the first instrument to provide a practical and objective measurement of dark adaptation function, which is severely impaired in AMD, RP, and other macular degenerations. It is a valuable complement to existing imaging devices used in routine eye exams for retinal disease assessment. This additional information is particularly valuable for early assessment, as biological function is often affected earlier than structural changes can be identified.
Preserving Vision Before It's Too Late
Gregory R. Jackson, PhD, Chief Scientific Officer, MacuLogix, discusses the promise of the AdaptDx as a test for impaired dark adaptation that occurs in patients with macular degeneration, a disorder that affects millions of people, and often goes undiagnosed for years.